Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, January 21st.

Anavex Life Sciences Stock Performance

Shares of AVXL stock opened at $9.57 on Tuesday. The firm has a market capitalization of $811.73 million, a price-to-earnings ratio of -18.40 and a beta of 0.70. Anavex Life Sciences has a one year low of $3.25 and a one year high of $14.44. The company has a 50 day moving average price of $9.99 and a 200 day moving average price of $7.52.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities analysts forecast that Anavex Life Sciences will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

A number of hedge funds have recently made changes to their positions in AVXL. Orion Capital Management LLC boosted its position in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares during the period. PVG Asset Management Corp acquired a new position in shares of Anavex Life Sciences during the third quarter worth about $74,000. Atria Investments Inc purchased a new stake in shares of Anavex Life Sciences in the third quarter worth about $76,000. BNP Paribas Financial Markets grew its stake in shares of Anavex Life Sciences by 97.0% in the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 7,421 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Anavex Life Sciences by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 6,366 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.